Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXSM Axsome Therapeutics	$102.89 +1.3%	$106.56	$72.02 ▼ $139.13	$5.00B	0.47	677,064 shs	650,414 shs
LNTH Lantheus	$78.99 +1.4%	$87.64	$73.11 ▼ $126.89	$5.39B	0.11	1.02 million shs	942,075 shs
NUVL Nuvalent	$75.53 -0.7%	$73.55	$55.54 ▼ $113.51	$5.46B	1.34	493,725 shs	360,890 shs
VERA Vera Therapeutics	$20.92 -1.1%	$22.54	$18.53 ▼ $51.61	$1.35B	1.13	958,748 shs	1.34 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXSM Axsome Therapeutics	+1.27%	-4.80%	-5.00%	-18.52%	+35.35%
LNTH Lantheus	+1.37%	-2.18%	+0.95%	-20.09%	-2.64%
NUVL Nuvalent	-0.70%	-1.79%	+3.03%	-2.72%	-3.29%
VERA Vera Therapeutics	-1.09%	-5.34%	-0.43%	-24.48%	-41.12%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AXSM Axsome Therapeutics	4.6954 of 5 stars	4.5	2.0	4.5	1.8	4.2	0.6
LNTH Lantheus	4.3475 of 5 stars	3.5	1.0	4.2	2.1	2.5	1.9
NUVL Nuvalent	2.4788 of 5 stars	3.5	2.0	0.0	2.3	3.3	0.0
VERA Vera Therapeutics	3.0225 of 5 stars	4.6	1.0	0.0	2.7	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXSM Axsome Therapeutics	3.06	Buy	$172.33	67.49% Upside
LNTH Lantheus	3.00	Buy	$132.67	67.95% Upside
NUVL Nuvalent	2.90	Moderate Buy	$115.50	52.92% Upside
VERA Vera Therapeutics	3.10	Buy	$65.00	210.71% Upside

Current Analyst Ratings Breakdown

Latest VERA, NUVL, LNTH, and AXSM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/12/2025	AXSM Axsome Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$193.00 ➝ $186.00
6/10/2025	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$180.00
6/9/2025	AXSM Axsome Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$153.00 ➝ $150.00
6/3/2025	VERA Vera Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
6/3/2025	VERA Vera Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
6/3/2025	AXSM Axsome Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$185.00
6/2/2025	VERA Vera Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Sector Outperform ➝ Sector Outperform	$55.00 ➝ $65.00
6/2/2025	VERA Vera Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $85.00
5/22/2025	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$180.00 ➝ $180.00
5/14/2025	AXSM Axsome Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/8/2025	LNTH Lantheus	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$127.00 ➝ $117.00

(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXSM Axsome Therapeutics	$385.69M	13.14	N/A	N/A	$1.18 per share	87.19
LNTH Lantheus	$1.53B	3.56	$7.19 per share	10.98	$15.65 per share	5.05
NUVL Nuvalent	N/A	N/A	N/A	N/A	$14.99 per share	N/A
VERA Vera Therapeutics	N/A	N/A	N/A	N/A	$9.08 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXSM Axsome Therapeutics	-$287.22M	-$5.77	N/A	36.49	N/A	-64.39%	-272.80%	-36.69%	8/4/2025 (Estimated)
LNTH Lantheus	$312.44M	$3.52	22.44	12.52	N/A	16.55%	36.99%	20.55%	7/30/2025 (Estimated)
NUVL Nuvalent	-$260.76M	-$4.39	N/A	N/A	N/A	N/A	-31.35%	-29.27%	8/14/2025 (Estimated)
VERA Vera Therapeutics	-$152.15M	-$3.00	N/A	N/A	N/A	N/A	-40.59%	-34.54%	8/6/2025 (Estimated)

Latest VERA, NUVL, LNTH, and AXSM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	NUVL Nuvalent	-$1.14	-$1.18	-$0.04	-$1.18	N/A	N/A
5/8/2025	Q1 2025	VERA Vera Therapeutics	-$0.75	-$0.81	-$0.06	-$0.81	N/A	N/A
5/7/2025	Q1 2025	LNTH Lantheus	$1.64	$1.53	-$0.11	$1.02	$377.37 million	$372.76 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A
NUVL Nuvalent	N/A	N/A	N/A	N/A	N/A
VERA Vera Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXSM Axsome Therapeutics	3.48	2.03	1.96
LNTH Lantheus	0.49	5.74	5.46
NUVL Nuvalent	N/A	14.48	14.48
VERA Vera Therapeutics	0.10	27.68	27.68

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXSM Axsome Therapeutics	81.49%
LNTH Lantheus	99.06%
NUVL Nuvalent	97.26%
VERA Vera Therapeutics	99.21%

Insider Ownership

Company	Insider Ownership
AXSM Axsome Therapeutics	22.30%
LNTH Lantheus	1.50%
NUVL Nuvalent	10.20%
VERA Vera Therapeutics	16.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXSM Axsome Therapeutics	380	49.24 million	38.26 million	Optionable
LNTH Lantheus	700	69.19 million	68.15 million	Optionable
NUVL Nuvalent	40	71.81 million	64.48 million	Optionable
VERA Vera Therapeutics	40	63.77 million	53.38 million	Optionable

VERA, NUVL, LNTH, and AXSM Headlines

Recent News About These Companies

J.P. Morgan Reaffirms Their Buy Rating on Vera Therapeutics (VERA)

June 19 at 1:32 AM | theglobeandmail.com

Vera Therapeutics, Inc. (NASDAQ:VERA) Short Interest Update

June 18 at 11:04 AM | marketbeat.com

Brokers Offer Predictions for VERA FY2026 Earnings

June 13, 2025 | americanbankingnews.com

Wedbush Equities Analysts Raise Earnings Estimates for VERA

June 13, 2025 | americanbankingnews.com

Analysts Can't Get Enough of These Little-Known Biopharma Stocks (VERA)

June 12, 2025 | marketbeat.com

Cantor Fitzgerald Comments on VERA FY2026 Earnings

June 11, 2025 | marketbeat.com

Q2 EPS Estimates for Vera Therapeutics Increased by Wedbush

June 11, 2025 | marketbeat.com

Vera Therapeutics Inc.

June 10, 2025 | barrons.com

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 9, 2025 | globenewswire.com

Vera Therapeutics (NASDAQ:VERA) Stock Price Down 5.2% - Here's What Happened

June 9, 2025 | marketbeat.com

Otsuka, Vera stake their claims to IgAN treatment

June 9, 2025 | pharmaphorum.com

Otsuka's kidney disease therapy trial results heat up battle with rival Vera

June 6, 2025 | msn.com

Vera Therapeutics (NASDAQ:VERA) Shares Gap Down - Should You Sell?

June 6, 2025 | marketbeat.com

Bank of America Corp DE Sells 106,673 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)

June 6, 2025 | marketbeat.com

Wedbush Increases Earnings Estimates for Vera Therapeutics

June 5, 2025 | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Position in Vera Therapeutics, Inc. (NASDAQ:VERA)

June 5, 2025 | marketbeat.com

Scotiabank Increases the Price Target for Vera Therapeutics by $10

June 4, 2025 | msn.com

Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

June 4, 2025 | globenewswire.com

Vera Therapeutics Atacicept: Promising Step In IgAN, But Crowded Road Ahead (Rating Downgrade)

June 4, 2025 | seekingalpha.com

FY2025 EPS Estimate for Vera Therapeutics Lowered by Analyst

June 4, 2025 | marketbeat.com

Vera Therapeutics (NASDAQ:VERA) Price Target Raised to $65.00 at Scotiabank

June 3, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
Analysts Think These Stocks Could More Than Double in Value
By Nathan Reiff | May 23, 2025
View Analysts Think These Stocks Could More Than Double in Value
Intel’s Turnaround May Be the Best Bet No One’s Watching
By Jeffrey Neal Johnson | May 30, 2025
View Intel’s Turnaround May Be the Best Bet No One’s Watching
Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
By Thomas Hughes | May 27, 2025
View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
5 Small-Cap Stocks to Watch for Big Speculative Gains
By Thomas Hughes | May 21, 2025
View 5 Small-Cap Stocks to Watch for Big Speculative Gains

VERA, NUVL, LNTH, and AXSM Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

$102.89 +1.29 (+1.27%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$101.66 -1.22 (-1.19%)

As of 06/18/2025 07:31 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Lantheus NASDAQ:LNTH

$78.99 +1.07 (+1.37%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$79.62 +0.63 (+0.80%)

As of 06/18/2025 07:29 PM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Nuvalent NASDAQ:NUVL

$75.53 -0.53 (-0.70%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$75.55 +0.02 (+0.03%)

As of 06/18/2025 04:39 PM Eastern

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Vera Therapeutics NASDAQ:VERA

$20.92 -0.23 (-1.09%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$20.83 -0.09 (-0.43%)

As of 06/18/2025 07:09 PM Eastern

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time